Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of this ...

Beyfortus is usually given by a healthcare provider in a hospital, clinic, or pediatrician’s office. Your child’s healthcare provider will make sure your child is receiving Beyfortus as scheduled.

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

An urgent warning has been issued by one Aussie health authority after medical staff reportedly gave the wrong RSV immunisations to patients.